SEHK:6990
SEHK:6990Biotechs

Global Stocks That May Be Priced Below Their Estimated Value In November 2025

As global markets navigate a complex landscape marked by mixed performances in major indices and shifting monetary policies, investors are closely watching for opportunities amid these fluctuations. The recent rate cuts by the Federal Reserve and the temporary trade truce between the U.S. and China have added layers of complexity to market dynamics, prompting a focus on stocks that may be undervalued relative to their estimated intrinsic value. In this environment, identifying undervalued...
SEHK:968
SEHK:968Semiconductor

Asian Market Insights: Zhejiang Taimei Medical Technology Among 3 Compelling Penny Stocks

The Asian markets have been closely watched as global economic dynamics shift, with the recent U.S.-China trade truce providing a temporary boost to investor sentiment. In this context, penny stocks, though often overlooked, can present intriguing opportunities when they exhibit robust financial health. These smaller or newer companies hold potential for growth and value that larger firms might not offer, and we will explore three such compelling stocks in the Asian market.
SEHK:2338
SEHK:2338Machinery

Top Asian Dividend Stocks To Watch In November 2025

As global markets navigate a complex landscape of interest rate adjustments and trade negotiations, Asian markets are also experiencing notable developments. With Japan's stock markets reaching record highs and China focusing on domestic demand to bolster growth, investors are increasingly interested in dividend stocks as a potential source of steady income amidst these shifting economic conditions. A good dividend stock often combines reliable payouts with the ability to adapt to evolving...
SEHK:3692
SEHK:3692Pharmaceuticals

Does Regulatory Progress for RET Inhibitor Reshape the Oncology Pipeline Momentum at Hansoh (SEHK:3692)?

The board of directors of Hansoh Pharmaceutical Group announced that China's National Medical Products Administration has accepted the New Drug Application for HS-10365 capsules, a selective RET inhibitor for treating adult patients with RET fusion-positive locally advanced or metastatic non-small cell lung cancer. This regulatory milestone not only reflects progress in Hansoh’s oncology pipeline, but also highlights the company’s potential to address significant unmet needs in lung cancer...
SEHK:1286
SEHK:1286Machinery

A Look at Impro Precision Industries (SEHK:1286) Valuation Following Strong Q3 Revenue Growth and Momentum

Impro Precision Industries (SEHK:1286) just posted a strong year-on-year jump in third quarter revenue, with standout gains in its diversified industrials and AI-related segments. The company’s positive sales outlook continues to draw attention from investors. See our latest analysis for Impro Precision Industries. Momentum has clearly shifted in Impro Precision Industries’ favor, with the share price climbing 12.87% over the past month and surging 65% in the last quarter. That is part of a...
SEHK:9973
SEHK:9973Auto

Chery Automobile (SEHK:9973): Evaluating Valuation as Shares Trade in a Tight Range

Chery Automobile (SEHK:9973) has been trading in a relatively narrow range, with its share price closing at HK$32.38. Over the past month, the stock edged up by 1%, reflecting investors’ cautious optimism. See our latest analysis for Chery Automobile. Momentum has been fairly muted for Chery Automobile, as this year’s modest 1.4% share price return suggests investors are still waiting to see if recent progress translates into stronger growth. After a flurry of updates earlier in the year, the...
SEHK:2331
SEHK:2331Luxury

Li Ning (SEHK:2331): Assessing Valuation After Q3 2025 Earnings Call Spurs Investor Focus

Li Ning (SEHK:2331) just held its Q3 2025 earnings call, drawing focused attention from investors and analysts. These quarterly updates provide a revealing look at the company’s financial health and management’s outlook for the months ahead. See our latest analysis for Li Ning. Li Ning’s Q3 earnings call appears to have been a catalyst for movement, with the share price rising 1.75% on the day but pulling back 7.05% over the past week. While short-term volatility remains, the company’s total...